MidEuropa has signed an agreement to acquire a controlling stake in Famar, a pharmaceutical contract development and manufacturing organization (CDMO), from ECM Partners and Metric Capital Partners.

MidEuropa will invest alongside the management team and current shareholders, who will retain a minority stake. The transaction, which is subject to customary anti-trust and regulatory approvals, is expected to close in the second half of 2024.

Famar provides a full-service offering across the CDMO value-chain, with broad capabilities across multiple dosage forms including sterile, solids, semi-solids, and R&D services. It employs approximately 1,900 people working across a network of six manufacturing sites located across southern Europe with two complementary R&D centers.

Matthew Strassberg, Partner and Head of Healthcare Sector Practice at MidEuropa, commented: “Our investment in Famar demonstrates MidEuropa’s continued commitment to identify and support growing platforms in the healthcare sector, and once completed, will bring our total equity investments in the sector to well over €1bn. Famar is a growing European CDMO platform with a track record of strong execution, combined with a clear value creation potential and expansion ambitions. We are impressed with Famar’s growth and success under Kostas Rengis’ leadership over the past few years and are enthusiastic about the opportunity to support him and his team to further strengthen Famar’s relevance to its clients in its current markets and beyond.”

Konstantinos Rengis, CEO of Famar, said: “We are pleased to welcome MidEuropa as a strong and highly reputable healthcare investor who shares our vision and values. With their backing, we are well placed to further accelerate Famar’s growth, provide high quality service to our customers and support our growing team while contributing to the health and well-being of millions of patients worldwide. We are confident that MidEuropa’s long-standing track record in the sector will be instrumental for the Company’s continued success.”

Savvas Liasis, Chairman of the Board of ECM Partners, added: “I am confident that the company [Famar] will continue to thrive under MidEuropa’s stewardship and we look forward to continuing our support of Famar’s talented management team in the next phase of growth.”

More Pharma Acquisitions

Read Contract Pharma’s 2024 Pharmaceutical Industry Mergers & Acquisitions Roundup.